Galapagos reported EUR4.71M in Cost of Sales for its fiscal quarter ending in June of 2025.


Cost Of Sales Change Date
argenx SE USD 110.75M 29.94M Jun/2025
AstraZeneca USD 2.47B 232M Jun/2025
Biogen USD 605M 24.3M Jun/2025
Genmab DKK 57M 15M Jun/2025
Gilead Sciences USD 1.5B 39M Jun/2025
GlaxoSmithKline GBP 2.16B 241M Jun/2025
GRIFOLS EUR 1.15B 56.19M Jun/2025
Hikma Pharmaceutical USD 895M 82M Dec/2024
Incyte USD 78.77M 10.96M Jun/2025
Merck EUR 2.23B 93M Jun/2025
Neurocrine Biosciences USD 11.3M 2.1M Jun/2025
Novartis USD 3.32B 95M Jun/2025
Roche Holding CHF 4.13B 393.5M Dec/2024
Sanofi EUR 2.99B 103M Jun/2025
UCB EUR 901M 50M Dec/2024
Vertex Pharmaceuticals USD 407.5M 44.5M Jun/2025